A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This is a double- blind, multicenter, randomized Phase II study to evaluate the efficacy and
safety of AT-101 in combination with docetaxel in relapsed/refractory non-small cell lung
cancer